WallStSmart

CBRE Group Inc Class A (CBRE)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CBRE Group Inc Class A generates 618670% more annual revenue ($42.20B vs $6.82M). CBRE leads profitability with a 3.1% profit margin vs -40.7%. CBRE earns a higher WallStSmart Score of 66/100 (B-).

CBRE

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 5.0Value: 4.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.27

EUDA

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -47.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CBRESignificantly Overvalued (-18.8%)

Margin of Safety

-18.8%

Fair Value

$123.82

Current Price

$147.05

$23.23 premium

UndervaluedFair: $123.82Overvalued

Intrinsic value data unavailable for EUDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CBRE3 strengths · Avg: 8.7/10
EPS GrowthGrowth
98.1%10/10

Earnings expanding 98.1% YoY

PEG RatioValuation
1.008/10

Growing faster than its price suggests

Revenue GrowthGrowth
18.6%8/10

18.6% revenue growth

EUDA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.9%10/10

Revenue surging 78.9% year-over-year

Debt/EquityHealth
-0.5610/10

Conservative balance sheet, low leverage

Areas to Watch

CBRE4 concerns · Avg: 3.3/10
P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
3.1%3/10

3.1% margin — thin

Operating MarginProfitability
2.6%3/10

Operating margin of 2.6%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EUDA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$44.88M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-632,5772/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CBRE

The strongest argument for CBRE centers on EPS Growth, PEG Ratio, Revenue Growth. Revenue growth of 18.6% demonstrates continued momentum. PEG of 1.00 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on Revenue Growth, Debt/Equity. Revenue growth of 78.9% demonstrates continued momentum.

Bear Case : CBRE

The primary concerns for CBRE are P/E Ratio, Profit Margin, Operating Margin. Thin 3.1% margins leave little buffer for downturns.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

CBRE profiles as a growth stock while EUDA is a hypergrowth play — different risk/reward profiles.

CBRE carries more volatility with a beta of 1.21 — expect wider price swings.

EUDA is growing revenue faster at 78.9% — sustainability is the question.

EUDA generates stronger free cash flow (-632,577), providing more financial flexibility.

Bottom Line

CBRE scores higher overall (66/100 vs 24/100) and 18.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CBRE Group Inc Class A

REAL ESTATE · REAL ESTATE SERVICES · USA

CBRE Group, Inc. is an American commercial real estate services and investment firm. The abbreviation CBRE stands for Coldwell Banker Richard Ellis. It is the largest commercial real estate services company in the world.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a forward-looking biopharmaceutical company focused on innovating treatments for rare diseases and addressing unmet medical needs. Leveraging advanced technologies, the firm is developing a robust clinical pipeline with a particular emphasis on supportive care and immune modulation. EUDA's strong commitment to research and development positions it favorably in the healthcare landscape, aiming to enhance patient outcomes and expand access to crucial therapies.

Visit Website →

Want to dig deeper into these stocks?